The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2020 | Nivolumab, ipilimumab and panitumumab in mCRC
Stacey Cohen, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the rationale and study design of a Phase II clinical trial investigating the clinical efficacy of nivolumab, ipilimumab, and panitumumab in patients with unresectable refractory KRAS/NRAS/BRAF wild-type microsatellite stable metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
